Back to search

Article

Treatment of Elderly Patients with Advanced Pancreatic Ductal Adenocarcinoma Utilizing a Metronomic Dose and Schedule of Chemotherapy: A Better Approach

2025-10-08

Abstract excerpt

<h4>Background: </h4> Pancreatic ductal adenocarcinoma (PDAC) is most prevalent in elderly patients, with a median age of 70 years at the time of diagnosis. To our knowledge, there are no trials designed to evaluate the safety and efficacy of treatment for elderly patients with PDAC. The standard of care for PDAC employs the “maximum tolerated doses” of multidrug chemotherapy regimens. These regimens require exten...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
fa70eb28-b751-50fa-aa88-32ce6faf7e65
DOI
10.20944/preprints202510.0364.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Treatment of Elderly Patients with Advanced Pancreatic Ductal Adenocarcinoma Utilizing a Metronomic Dose and Schedule of Chemotherapy: A Better ApproachDOI 10.20944/preprints202510.0364.v1
Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy.Semantic proximity
Correlation Between Drug Sensitivity Profiles of Ex Vivo Expanded Circulating Tumor Cells and Clinical Treatment Response in Pancreatic Ductal Adenocarcinoma PatientsSemantic proximity
Chemotherapy and targeted therapy for advanced biliary tract cancers：An umbrella reviewSemantic proximity
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.Semantic proximity
Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD studySemantic proximity
Pancreatic ductal adenocarcinoma treatment--the past, present, and future.Semantic proximity
Therapeutic Targeting of Oncogene-induced Transcription-Replication Conflicts in Pancreatic Ductal AdenocarcinomaSemantic proximity
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.Semantic proximity
Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity
Paricalcitol and hydroxychloroquine modulates extracellular matrix and enhance chemotherapy efficacy in pancreatic cancerSemantic proximity
Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic CancerSemantic proximity
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.Semantic proximity
Select a neighboring publication to make it the new centre.